Q3 2022 13F Holders as of 9/30/2022
-
Type / Class
-
Equity / Common Stock, $0.001 par value per share
-
Shares outstanding
-
122M
-
Number of holders
-
37
-
Total 13F shares, excl. options
-
45.8M
-
Shares change
-
+17M
-
Total reported value, excl. options
-
$70.5M
-
Value change
-
+$26.2M
-
Number of buys
-
23
-
Number of sells
-
-12
-
Price
-
$1.54
Significant Holders of Trevi Therapeutics, Inc. - Common Stock, $0.001 par value per share (TRVI) as of Q3 2022
40 filings reported holding TRVI - Trevi Therapeutics, Inc. - Common Stock, $0.001 par value per share as of Q3 2022.
Trevi Therapeutics, Inc. - Common Stock, $0.001 par value per share (TRVI) has 37 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 45.8M shares
of 122M outstanding shares and own 37.66% of the company stock.
Largest 10 shareholders include NEA Management Company, LLC (11.4M shares), Fairmount Funds Management LLC (5.7M shares), Rubric Capital Management LP (5.68M shares), Frazier Life Sciences Management, L.P. (5.4M shares), VIKING GLOBAL INVESTORS LP (4.4M shares), VR Adviser, LLC (3.05M shares), MAI Capital Management (2.02M shares), FMR LLC (1.56M shares), VANGUARD GROUP INC (1.32M shares), and Altium Capital Management LP (1.07M shares).
This table shows the top 37 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.